GuruFocus · OS · October 24, 2026

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Get the app for more

Explore stock news, insights and company research.